These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30247984)

  • 1. Ferroportin disease mutations influence manganese accumulation and cytotoxicity.
    Choi EK; Nguyen TT; Iwase S; Seo YA
    FASEB J; 2019 Feb; 33(2):2228-2240. PubMed ID: 30247984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferroportin is a manganese-responsive protein that decreases manganese cytotoxicity and accumulation.
    Yin Z; Jiang H; Lee ES; Ni M; Erikson KM; Milatovic D; Bowman AB; Aschner M
    J Neurochem; 2010 Mar; 112(5):1190-8. PubMed ID: 20002294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The iron transporter ferroportin can also function as a manganese exporter.
    Madejczyk MS; Ballatori N
    Biochim Biophys Acta; 2012 Mar; 1818(3):651-7. PubMed ID: 22178646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis.
    Jin L; Frazer DM; Lu Y; Wilkins SJ; Ayton S; Bush A; Anderson GJ
    Metallomics; 2019 May; 11(5):959-967. PubMed ID: 30888356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferroportin deficiency impairs manganese metabolism in flatiron mice.
    Seo YA; Wessling-Resnick M
    FASEB J; 2015 Jul; 29(7):2726-33. PubMed ID: 25782988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
    Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
    Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations.
    DeWitt MR; Chen P; Aschner M
    Biochem Biophys Res Commun; 2013 Mar; 432(1):1-4. PubMed ID: 23357421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
    Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
    Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the functional properties of human and mouse ferroportin.
    Azucenas CR; Ruwe TA; Bonamer JP; Qiao B; Ganz T; Jormakka M; Nemeth E; Mackenzie B
    Am J Physiol Cell Physiol; 2023 May; 324(5):C1110-C1118. PubMed ID: 36939203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of manganese and other biometals in flatiron mice.
    Seo YA; Elkhader JA; Wessling-Resnick M
    Biometals; 2016 Feb; 29(1):147-55. PubMed ID: 26693922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular model of the ferroportin intracellular gate and implications for the human iron transport cycle and hemochromatosis type 4A.
    Guellec J; Elbahnsi A; Tertre ML; Uguen K; Gourlaouen I; Férec C; Ka C; Callebaut I; Gac GL
    FASEB J; 2019 Dec; 33(12):14625-14635. PubMed ID: 31690120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
    Rishi G; Secondes ES; Wallace DF; Subramaniam VN
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manganese transport and toxicity in polarized WIF-B hepatocytes.
    Thompson KJ; Hein J; Baez A; Sosa JC; Wessling-Resnick M
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G351-G363. PubMed ID: 29792530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
    Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
    Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-mutagenic Suppression of Enterocyte Ferroportin 1 by Chemical Ribosomal Inactivation via p38 Mitogen-activated Protein Kinase (MAPK)-mediated Regulation: EVIDENCE FOR ENVIRONMENTAL HEMOCHROMATOSIS.
    Oh CK; Park SH; Kim J; Moon Y
    J Biol Chem; 2016 Sep; 291(38):19858-72. PubMed ID: 27445333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
    Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
    Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular basis of ferroportin-linked hemochromatosis.
    De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
    Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption of manganese and iron in a mouse model of hemochromatosis.
    Kim J; Buckett PD; Wessling-Resnick M
    PLoS One; 2013; 8(5):e64944. PubMed ID: 23705020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ferroportin polymorphism on iron homeostasis and infection.
    Kasvosve I
    Clin Chim Acta; 2013 Feb; 416():20-5. PubMed ID: 23178444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
    Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
    Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.